Bot Detector
IJPC Seal
Download FREE Sample Issue or Article
LEARN MORE
Subscribe Today
A subscription to IJPC provides on-line access to full-text, full-color, printable PDF copies of your subscribed issues, individual articles, and purchased archives.

Compounded Topical Gabapentin for Neuropathic Pain: Does Choice of Base Affect Efficacy?

Author(s):  Shakshuki Ayah, Agu Remigius U

Issue:  Nov/Dec 2019 - Volume 23, Number 6
View All Articles in Issue

Page(s):  496-503

Compounded Topical Gabapentin for Neuropathic Pain: Does Choice of Base Affect Efficacy? Page 1
Compounded Topical Gabapentin for Neuropathic Pain: Does Choice of Base Affect Efficacy? Page 2
Compounded Topical Gabapentin for Neuropathic Pain: Does Choice of Base Affect Efficacy? Page 3
Compounded Topical Gabapentin for Neuropathic Pain: Does Choice of Base Affect Efficacy? Page 4
Compounded Topical Gabapentin for Neuropathic Pain: Does Choice of Base Affect Efficacy? Page 5
Compounded Topical Gabapentin for Neuropathic Pain: Does Choice of Base Affect Efficacy? Page 6
Compounded Topical Gabapentin for Neuropathic Pain: Does Choice of Base Affect Efficacy? Page 7
Compounded Topical Gabapentin for Neuropathic Pain: Does Choice of Base Affect Efficacy? Page 8

Download in electronic PDF format for $75

Abstract:  The objective of this study was to investigate the effect of Lipoderm Cream, VersaBase Gel, and Emollient Cream on the release and permeation of gabapentin formulated for neuropathic pain. Gabapentin of different strengths (1%, 5%, and 10%) was compounded with the bases, diffusion of the drug from thebases, and permeation through artificial skin model studied with Franz diffusionsystem. Steady-state flux, cumulative permeation, and lag times were calculated,and release mechanisms modelled with first order, second-order, Higuchi, Korsmeyer-Peppas, and Hixon-Crowell kinetic models. Gabapentin recovery from VersaBase Gel, Lipoderm Cream, and Emollient Cream was 100.8 ± 2.7%, 101.3 ± 1.2%, and 104.9 ± 3.3%, respectively. Gabapentin completely diffused out of the three bases within 6 hours of application according to the Higuchi model. Flux of the drug appeared to be concentration-dependent with no permeation occurring at 1% strength. Whereas, 5% and 10% strengths in Lipoderm Cream permeated the skin rapidly, the same concentrations in Emollient Cream and VersaBase Gel required 60-minutes and 120-minutes lag times, respectively. For the three bases, a strong correlation was observed between lag times and flux. The overall permeation in VersaBase Gel and Lipoderm Base was not significantly different (P>0.05). However, Emollient Cream resulted in a significantly lower total permeation compared to other bases (P<0.05). As the formulations are for pain management, products with no lag times and higher flux are preferable. Although VersaBase Gel and Emollient Cream displayed some gabapentin permeability, it is important to consider gabapentin stability in these bases prior to use.

Related Keywords: gabapentin, voltage-dependent calcium channel inhibitor, NMDA inhibitor, topical preparation, cream base, gel base, neuropathic pain, pain relief, postherpetic neuralgia, skin permeation, drug release modeling, simulated human skin

Related Categories: EXCIPIENTS, PAIN MANAGEMENT, PEER-REVIEWED, DOSAGE FORMS/DRUG CARRIERS, MUSCULOSKELETAL DISORDERS, NEUROLOGY

Printer-Friendly Version



Related Articles from IJPC
Title/Author
(Click for Abstract / Details / Purchase)
Issue/​Page
View/Buy
Compounded Topical Gabapentin for Neuropathic Pain: Does Choice of Base Affect Efficacy?
Shakshuki Ayah
, Agu Remigius U
Nov/Dec 2019
Pg. 496-503

Compounding Pearls -- Wound Care: Base Selection
Riepl Mike
Mar/Apr 2020
Pg. 98-102

Topical Medications for Orofacial Neuropathic Pain
Bramwell Bethany L
May/Jun 2010
Pg. 200-203

Compounded Analgesic Therapy for Disorders of Movement: Arthritis, Neuropathic Pain, and Postpolio Syndrome
Brown Scott
, Erickson Brian, Muller George, Bryant-Snure Susan J, Mestayer Richard F III
May/Jun 2010
Pg. 182-192

Analgesic Efficacy and Transdermal Penetration of Topical Gabapentin Creams: Finding an Optimal Dose and Pre-treatment Time
Heustess Allie
, Spigener Shuler, Sweitzer Sarah, Romero-Sandoval Alfonso, Asbill Scott
Mar/Apr 2015
Pg. 167-173

Basics of Compounding: Excipients Used in Nonsterile Compounding, Part 10: Rectal Suppository Bases
Allen Loyd V Jr
Jul/Aug 2021
Pg. 304-309

Physical Stability and Release Profile of Compounded Gabapentin Containing Pluronic Lecithin Organogel for Neuropathic Pain Management
Hong Eun Ji
, Sumanasekera Wasana, Le Uyen Minh
Jan/Feb 2022
Pg. 65-71

Efficacy and Clinical Value of Commonly Used Ingredients in Pain Management Compounds: A Literature Review
Beshay Sarah M
, Rivera Gerard, Balthasar Jan, Florea Naomi
Mar/Apr 2024
Pg. 111-116

Efficacy and Clinical Value of Commonly Used Ingredients in Pain Management Compounds: A Literature Review
Beshay Sarah M
, Rivera Gerard, Balthasar Jan, Florea Naomi
Jul/Aug 2015
Pg. 295-300

Clinical Nuggets and Pearls: Chronic Neuropathic Pain and Opioid Tolerance
Jones Marty
Jan/Feb 2002
Pg. 4-6

Topical Treatment of Neuropathic Pain
Vadaurri Vince
May/Jun 2008
Pg. 182-190

Compounded Pain Formulations: What is the Evidence?
Asbill Scott
, Sweitzer Sarah M, Spigener Shuler, Romero-Sandoval Alfonso
Mar/Apr 2024
Pg. 100-109

Compounded Pain Formulations: What is the Evidence?
Asbill Scott
, Sweitzer Sarah M, Spigener Shuler, Romero-Sandoval Alfonso
Jul/Aug 2014
Pg. 278-286

Update on Managing Neuropathic Pain
McNulty Jack P
, Muller George
May/Jun 2009
Pg. 182-190

Topical Ketamine 10% for Neuropathic Pain in Spinal Cord Injury Patients: An Open-Label Trial
Rabi Joseph
, Minori Joshua, Abad Hasan, Lee Ray, Gittler Michelle
Nov/Dec 2016
Pg. 517-520

Chronic Neuropathic Pain: Pharmacological Interventions in New Millennium
Jones Marty
Jan/Feb 2000
Pg. 6-15

Current Topical Treatments in Wound Healing - Part 1
Helmke Christopher D
Jul/Aug 2004
Pg. 269-274

Gabapentin 50-mg/mL in SyrSpend SF Oral Suspension
Allen Loyd V Jr
Nov/Dec 2019
Pg. 486

Stability of Compounded Topical Nifedipine in Cream, Gel, and Ointment Bases
Teimouri Arezou
, Yeung Pollen, Agu Remigius U
Jul/Aug 2021
Pg. 344-351

Topical Oil-in-Water Cream Bases, Featured Excipient:
Allen Loyd V Jr
Jul/Aug 2002
Pg. 303-304

Return to Top